Hydrocortisone Renata (Hydrocortisone)

Hydrocortisone Renata is used in clinical practice to replace deficient cortisol and to manage inflammatory or autoimmune processes that require systemic glucocorticoid therapy.

• Primary adrenal insufficiency (Addison’s disease)
• Secondary adrenal insufficiency due to pituitary or hypothalamic disorders
• Acute adrenal crisis requiring rapid cortisol replacement
• Chronic inflammatory conditions such as rheumatoid arthritis, systemic lupus erythematosus, and inflammatory bowel disease
• Severe allergic reactions or asthma exacerbations when oral glucocorticoid therapy is indicated
• Certain dermatologic or ophthalmic autoimmune disorders requiring systemic treatment

• Hydrocortisone binds to intracellular glucocorticoid receptors, forming a hormone‑receptor complex that translocates to the nucleus and modulates gene transcription. This interaction up‑regulates anti‑inflammatory proteins such as annexin‑1 and down‑regulates pro‑inflammatory cytokines, chemokines, and adhesion molecules. The net effect is reduced synthesis of prostaglandins and leukotrienes, suppression of immune cell activation, and restoration of physiologic cortisol levels in patients with adrenal insufficiency.

Oral hydrocortisone may be associated with a range of adverse reactions, varying in frequency and severity.

Common

• Mild gastrointestinal discomfort, nausea, or abdominal pain
• Transient increase in blood glucose levels
• Fluid retention leading to mild edema
• Mood changes such as irritability or mild insomnia
• Acne or skin thinning with prolonged use

Serious

• Severe hyperglycemia or new‑onset diabetes mellitus
• Hypertension or worsening of pre‑existing high blood pressure
• Opportunistic infections due to immunosuppression
• Osteoporosis or pathological fractures with long‑term therapy
• Adrenal suppression leading to adrenal crisis upon abrupt discontinuation

Before initiating Hydrocortisone Renata, clinicians should evaluate several safety considerations to minimize risk.

• Assess for active infections, especially tuberculosis or systemic fungal disease, as glucocorticoids can worsen them.
• Review patient history for uncontrolled diabetes, hypertension, or peptic ulcer disease.
• Use the lowest effective dose for the shortest duration possible to reduce long‑term complications.
• Monitor serum electrolytes, blood glucose, and blood pressure regularly during therapy.
• Caution in patients with known hypersensitivity to hydrocortisone or other corticosteroids.
• Evaluate bone health in individuals at risk for osteoporosis, particularly with prolonged use.
• Consider stress‑dose adjustments in patients undergoing surgery or severe physiological stress.

Hydrocortisone can interact with other medicines, altering its effectiveness or increasing the risk of adverse effects.

Avoid

• Potent CYP3A4 inducers such as rifampin, phenytoin, or carbamazepine, which may reduce hydrocortisone plasma concentrations.
• Systemic antifungal agents (e.g., ketoconazole, itraconazole) that can increase glucocorticoid levels and risk of toxicity.

Use with caution

• Non‑steroidal anti‑inflammatory drugs (NSAIDs) because combined use may raise the risk of gastrointestinal bleeding or ulceration.
• Anticoagulants (e.g., warfarin) as glucocorticoids may affect coagulation parameters.
• Diabetic medications, since hydrocortisone can raise blood glucose and may require dose adjustments.
• Vaccines, particularly live attenuated vaccines, because immunosuppression may diminish vaccine efficacy.